Support The Moscow Times!

EBRD Lends $6.55M to Geropharm Drug Maker

The European Bank for Reconstruction and Development has provided a 5 million euro ($6.55 million) loan to Geropharm, one of Russia's leading pharmaceutical companies, to help it upgrade its drug manufacturing plant in Obolensk in the Moscow region.

The loan was issued for five years to Geropharm-Bio, a Geropharm subsidiary, the EBRD said in a statement Wednesday. It is expected to help the company meet the Good Manufacturing Practices standard.

The company plans to install a new filling and packaging line for existing products. The company's insulin production will more than double as a result. Geropharm also plans to shift its production line to more profitable drugs.

In 2011, the value of Russia's pharmaceutical market was estimated at nearly $21 billion, with domestically manufactured drugs accounting for only around 22 percent of this amount.

The EBRD has so far invested more than 150 million euros in Russia's pharmaceutical and healthcare industries.

Geropharm is a privately owned manufacturer and distributor of human insulin and other drugs.

Related articles:

… we have a small favor to ask. As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more